GSK is making significant strides in the prevention of shingles, a painful viral condition caused by the reactivation of the varicella-zoster virus. Recent clinical studies and public health initiatives underscore GSK’s commitment to expanding access to its recombinant shingles vaccine, demonstrating high efficacy across adult populations, including older and immunocompromised individuals. Experts note that effective prevention reduces healthcare costs, Rs.-denominated treatment burdens, and long-term complications such as postherpetic neuralgia.